Technetium 99m labelled ethylenedicysteine (EC) amifostine (99mTc-EC-amifostine), is a theranostic agent, being developed by Cellpoint, for detection and treatment of COVID-2019 infections as well as detection of cancers arising from viral infections by using EC drug conjugate platform. The company has in-licensed the EC platform from the M.D. Anderson Cancer Center, wherein tissue specific ligands or pharmaceutical compounds are linked to cold metals or radioisotopes. Upon targeted delivery in the organ, EC-Amifostine which is an organic thiophosphate with oxygen scavenging activity, metabolised by alkaline phosphatase (ALP) present on neutrophil surface to an active thiol analog, which scavenge free-radicals and stabilise DNA to protect the infected or organs. 99mTc-EC-amifostine can be detected using both PET and SPECT for imaging to assess location and degree of COVID-2019 infection and associated damage as well as follow-up confirmatory imaging to determine post treatment resolution. 99mTc-EC-amifostine can be used to differentiate the extent of tumour progression and the degree of viral infection involvement with tumour proliferation. Amifostine was originally developed by the Southern Research Institute in Birmingham, Alabama, USA. Early-stage development is underway in the US.